Literature DB >> 9255201

Economic evaluation of respiratory syncytial virus infection in Canadian children: a Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study.

J M Langley1, E E Wang, B J Law, D Stephens, F D Boucher, S Dobson, J McDonald, N E MacDonald, I Mitchell, J L Robinson.   

Abstract

OBJECTIVES: To quantify the cost and distribution of health care resources consumed annually in management of Canadian children from birth to 4 years of age with respiratory syncytial virus (RSV) infection. STUDY
DESIGN: Estimates of direct medical expenditures (in 1993 U.S. dollars) were collected from a prospective cohort study of hospitalized children with RSV and from national and provincial databases.
RESULTS: The annual cost of RSV-associated illness was almost $18 million. The largest component of direct expenditures (62%) was for inpatient care for the estimated 0.7% of all infected children ill enough to require admission. Physician fees comprised only 4% of inpatient expenses. Expenditures for ambulatory patients accounted for 38% of direct costs.
CONCLUSIONS: The greatest reductions in the economic cost of RSV infections will be found in interventions that reduce duration of or prevent hospital stay. Costs for management of RSV infection in children in the Canadian health care system are considerably less than charges reported in the United States.

Entities:  

Mesh:

Year:  1997        PMID: 9255201     DOI: 10.1016/s0022-3476(97)70133-1

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  34 in total

1.  Respiratory syncytial virus immune globulin intravenous.

Authors: 
Journal:  Paediatr Child Health       Date:  1998-01       Impact factor: 2.253

2.  Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent?

Authors:  B Law; N Macdonald; J Langley; I Mitchell; D Stephens; E Wang; J Robinson; F Boucher; J McDonald; S Dobson
Journal:  Paediatr Child Health       Date:  1998-11       Impact factor: 2.253

3.  A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.

Authors:  Bosco A Paes; Ian Mitchell; Anna Banerji; Krista L Lanctôt; Joanne M Langley
Journal:  Can Respir J       Date:  2011 Mar-Apr       Impact factor: 2.409

4.  Net cost of palivizumab for respiratory syncytial virus prophylaxis during the 1998/99 season in northern Alberta.

Authors:  S L Lee; P Etches; J L Robinson
Journal:  Paediatr Child Health       Date:  2001-10       Impact factor: 2.253

5.  Paediatric emergency research in Canada: Using the iterative loop of research as a paradigm for advancing the field.

Authors:  David W Johnson; Martin H Osmond; Nicola Hooton; Terry P Klassen
Journal:  Paediatr Child Health       Date:  2004-07       Impact factor: 2.253

6.  Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants.

Authors: 
Journal:  Paediatr Child Health       Date:  1999-10       Impact factor: 2.253

7.  The Pediatric Investigators Collaborative Network on Infections in Canada: A model for multicentre research collaboration.

Authors:  E E Wang
Journal:  Paediatr Child Health       Date:  1999-09       Impact factor: 2.253

8.  How much does it cost to manage paediatric tuberculosis? One-year experience from The Hospital for Sick Children.

Authors:  C L Main; E Ying; E E Wang
Journal:  Can J Infect Dis       Date:  1998-11

9.  The real-life effectiveness of palivizumab for reducing hospital admissions for respiratory syncytial virus in infants residing in Nunavut.

Authors:  Anna Banerji; Vladimir Panzov; Michael Young; Bonita E Lee; Muhammad Mamdani; B Louise Giles; Marguerite Dennis; Johanne Morel; Danny Bisson; Bosco A Paes; Charles Hui; Jim Mahony
Journal:  Can Respir J       Date:  2013-12-23       Impact factor: 2.409

10.  Improving outcomes for ill and injured children in emergency departments: protocol for a program in pediatric emergency medicine and knowledge translation science.

Authors:  Shannon Scott; Lisa Hartling; Jeremy Grimshaw; David Johnson; Martin Osmond; Amy Plint; Rollin Brant; Jamie C Brehaut; Ian D Graham; Gillian Currie; Nicola Shaw; Maala Bhatt; Tim Lynch; Liza Bialy; Terry Klassen
Journal:  Implement Sci       Date:  2009-09-22       Impact factor: 7.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.